Imugene Limited ( ($AU:IMU) ) has provided an update.
Imugene Limited has received an R&D tax refund of A$11.7 million for the 2023 financial year, which will support further clinical development of its immuno-oncology pipeline. This refund, part of the Australian Government’s R&D tax incentive, strengthens Imugene’s ability to advance its innovative cancer therapies, potentially enhancing its position in the global market for immuno-oncology treatments.
More about Imugene Limited
Imugene Limited is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system of cancer patients for tumor treatment and eradication. The company’s pipeline includes cell therapy CAR T drug azer-cel for blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers, supported by a team of international cancer experts.
YTD Price Performance: 50.0%
Average Trading Volume: 160,971
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $207.6M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.
